Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide
Biomedical Materials · 2025
DOI: 10.1088/1748-605x/adb2cf ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Materials, 2025. Verfasst von Ben Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 401135, People's Republic of China. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Chitosan, Surface-Active Agents, Liposomes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Science and Technology Research Program of Chongqing Municipal Education Commission, the Chongqing Natural Science Foundation Postdoctoral Science Fund Project.
Abstract (Originalsprache)
Diabetes is now a global chronic disease, with the number of people with diabetes expected to reach 643 million by the end of 2030. Semaglutide, a human glucagon-like peptide-1 (GLP-1) analogue with 94% similarity to human GLP-1, can promote insulin secretion and repress glucagon secretion in a glucose concentration-dependent manner, resulting in substantial improvement of blood glucose levels and reducing the risk of hypoglycemia in patients with type 2 diabetes. To improve the absorption efficiency of semaglutide in oral delivery, we developed chitosan hydrochloride-coated and nonionic surfactant-modified niosomes (CS.HCL-NSPEs-NIO) as a new way to encapsulate it. The results showed that CS.HCL-NSPEs-NIO could efficiently penetrate the cell junctions in the intestinal endothelium and therefore promote drug absorbance. In addition, gastrointestinal distribution studies revealed that CS. HCL-NSPEs-NIO could stay in the intestine for more than 4 h, thus allowing for long-term glucose regulation. Effective reduction of blood glucose levels and weight loss were observed in db/db mice while no toxicity was detected in major organs. On the whole, our recommendation is that CS.HCL-NSPEs-NIO shows promise as an oral delivery tool for enhancing the hypoglycemic effects of semaglutide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing 401135, People's Republic of China.
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd, Chengdu 611138, Sichuan, People's Republic of China.
- Hunan Kelun Pharmaceutical Research Co. Ltd, Yueyang 414000, Hunan, People's Republic of China.
ORCID-Profile: Jing Xie, Yaqin Tang
Förderung
- the National Natural Science Foundation of China
- Science and Technology Research Program of Chongqing Municipal Education Commission
- the Chongqing Natural Science Foundation Postdoctoral Science Fund Project
- the Natural Science Foundation Project of CQCSTC
- Natural Science Foundation Project of CQCSTC
Zitieren
APA
Wang, B., Su, Z., Kuang, M., Luo, Y., Xu, M., Sun, M., Liu, X., Guo, Y., Bai, L., Wang, Y., Yan, X., Xie, J., & Tang, Y. (2025). Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide. Biomedical Materials. https://doi.org/10.1088/1748-605x/adb2cf
Vancouver
Wang B, Su Z, Kuang M, Luo Y, Xu M, Sun M, et al. Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide. Biomedical Materials. 2025. doi:10.1088/1748-605x/adb2cf
BibTeX
@article{Wang2025,
author = {Wang, Ben and Su, Zhengxing and Kuang, Meiyan and Luo, Yi and Xu, Minhao and Sun, Meng and Liu, Xingyou and Guo, Yue and Bai, Lu and Wang, Yu and Yan, Xinlei and Xie, Jing and Tang, Yaqin},
title = {Chitosan hydrochloride coated and nonionic surfactant modified niosomes: a better way for oral administration of semaglutide},
journal = {Biomedical Materials},
year = {2025},
doi = {10.1088/1748-605x/adb2cf}
}
EUVIMED